Founder and CEO
Manijeh Goldberg is the Founder and CEO of Privo Technologies, a pioneering biopharmaceutical company revolutionizing localized drug delivery for oncology. With over 20 years of experience, including leadership roles in five startups (one acquired for $475M), she has a proven track record in strategy, fundraising, and commercialization. Under her leadership, Privo has secured significant non-dilutive funding from NIH and NCF, established key partnerships with the National Cancer Institute (NCI) and the National Institute of Dental and Craniofacial Research (NIDCR), and advanced multiple clinical-stage therapeutics.
Privo’s flagship product, PRV111, a topical treatment for early carcinomas, is in late-stage clinical trials, demonstrating significant tumor reduction and strong commercial potential. Additionally, PRV211 and PRV131 target residual and large solid tumors, expanding Privo’s pipeline and market reach. Manijeh has been instrumental in securing investment, leveraging non-dilutive funding, strategic partnerships, and investor relations to drive growth and maximize company valuation.
Recognized as a leader in oncology innovation, she was named AIM-HI Best Woman-Owned Oncology Company and received the TIBIT Award at the White House for her contributions to biomedical innovation. Her recent publication in Nature Communications highlights the success of Privo’s CLN-001 clinical trial, further solidifying the company’s scientific and commercial impact.
Manijeh holds a Ph.D. in Biomedical Engineering, an MBA from MIT Sloan, and degrees from Harvard Medical School, uniquely positioning her to bridge scientific discovery with commercialization, drive business development, and scale Privo into a market leader in oncology therapeutics.